Related Experiment Video
Updated: Jul 15, 2026
07:14
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
Published on: July 11, 2025
Tafenoquine: a promising new antimalarial agent
Maryanne Crockett1, Kevin C Kain
1The Hospital for Sick Children, Division of Infectious Diseases, 555 University Avenue, Toronto, M5G 1X8, Canada. maryanne.crockett@utoronto.ca
Expert Opinion on Investigational Drugs
|April 28, 2007
Summary
Tafenoquine, a new antimalarial drug, shows over 90% efficacy in preventing and treating malaria caused by Plasmodium vivax and P. falciparum. It offers a promising alternative for malaria control, though not suitable for pregnant women or G6PD-deficient individuals.
Area of Science:
- Tropical medicine
- Infectious diseases
- Pharmacology
Background:
- Malaria remains a significant global health burden, with increasing antimalarial drug resistance necessitating novel therapeutic agents.
- The 8-aminoquinoline class of antimalarials is crucial for radical cure and prophylaxis, but resistance and side effects pose challenges.
Purpose of the Study:
- To evaluate the efficacy and safety of tafenoquine, an 8-aminoquinoline antimalarial, for the prevention and radical cure of malaria.
- To assess tafenoquine's potential as an alternative to existing antimalarial treatments.
Main Methods:
- Review of well-designed studies investigating tafenoquine's effectiveness.
- Assessment of tafenoquine's safety profile, including contraindications.
Main Results:
- Tafenoquine demonstrated high efficacy (>90%) in causal prophylaxis and radical cure for Plasmodium vivax and Plasmodium falciparum infections.
- The drug has a long half-life (approx. 14 days) and is generally safe and well-tolerated.
- Contraindications include pregnancy and glucose-6-phosphate dehydrogenase deficiency.
Conclusions:
- Tafenoquine is a highly effective antimalarial agent for both prevention and radical cure.
- Its causal activity and safety profile present tafenoquine as a valuable new option for malaria management.
- Careful patient selection is required due to specific contraindications.
Related Concept Videos
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:22American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...